MedPath
Found 19 clinical trials|View Analysis
Sort by:

A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma

Phase 3
Not yet recruiting
Conditions
Advanced Oesophageal Squamous Cell Carcinoma
Interventions
Drug: simmitinib
Drug: investigator's choice of chemotherapy,include docetaxel or irinotecan.
First Posted Date
2024-10-24
Last Posted Date
2024-10-24
Lead Sponsor
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Target Recruit Count
450
Registration Number
NCT06656091

A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer

Phase 3
Recruiting
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
First Posted Date
2024-01-08
Last Posted Date
2024-03-07
Lead Sponsor
Beijing Konruns Pharmaceutical Co., Ltd.
Target Recruit Count
490
Registration Number
NCT06194734
Locations
🇨🇳

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype

Phase 3
Recruiting
Conditions
Metastatic Breast Cancer
Mutation
Triple Negative Breast Cancer
Interventions
Drug: Investigator's Choice of Chemotherapy
Drug: Everolimus
First Posted Date
2023-07-20
Last Posted Date
2024-01-16
Lead Sponsor
Fudan University
Target Recruit Count
203
Registration Number
NCT05954442
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

Phase 3
Recruiting
Conditions
Advanced or Metastatic Urothelium Cancer
Interventions
First Posted Date
2023-03-06
Last Posted Date
2023-04-13
Lead Sponsor
Shanghai Miracogen Inc.
Target Recruit Count
290
Registration Number
NCT05754853
Locations
🇨🇳

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations

Phase 2
Recruiting
Conditions
Breast Cancer Metastatic
Interventions
Drug: TSL-1502 capsules(low dose)
Drug: Investigator's choice of chemotherapy
Drug: TSL-1502 capsules(high dose)
First Posted Date
2022-06-15
Last Posted Date
2024-05-08
Lead Sponsor
Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
Target Recruit Count
125
Registration Number
NCT05420779
Locations
🇨🇳

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

Phase 3
Active, not recruiting
Conditions
Early Breast Cancer
Locally Advanced Breast Cancer
Inflammatory Breast Cancer
Interventions
First Posted Date
2022-06-13
Last Posted Date
2024-12-24
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
347
Registration Number
NCT05415215
Locations
🇧🇦

University Clinical Center of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina

🇨🇷

Clinica CIMCA, San José, Costa Rica

🇵🇪

Instituto Regional de Enfermedades Neoplásicas del Sur; Centro de Inv. de Medicina Oncológica, Arequipa, Peru

and more 42 locations

A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma

Phase 3
Recruiting
Conditions
Hodgkin Disease Lymphoma
Interventions
Drug: Investigator's choice of Chemotherapy
Drug: Penpulimab
First Posted Date
2022-02-17
Last Posted Date
2022-02-17
Lead Sponsor
Akeso
Target Recruit Count
60
Registration Number
NCT05244642
Locations
🇨🇳

Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong, China

🇨🇳

Xiangya Hospital Central South University, Changsha, Hunan, China

🇨🇳

Qilu Hospital of Shandong University, Jinan, Shandong, China

and more 3 locations

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Phase 3
Active, not recruiting
Conditions
Breast Cancer
Interventions
First Posted Date
2021-11-03
Last Posted Date
2024-11-21
Lead Sponsor
AstraZeneca
Target Recruit Count
732
Registration Number
NCT05104866
Locations
🇬🇧

Research Site, Truro, United Kingdom

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

Phase 2
Completed
Conditions
Advanced Unresectable or Metastatic Solid Malignancy
Interventions
First Posted Date
2020-11-17
Last Posted Date
2025-01-08
Lead Sponsor
Genentech, Inc.
Target Recruit Count
252
Registration Number
NCT04632992
Locations
🇺🇸

Sarah Cannon Research Institute / Tennessee Oncology, Chattanooga, Tennessee, United States

🇺🇸

SCRI Oncology Partners, Nashville, Tennessee, United States

🇺🇸

Alaska Oncology and Hematology, Anchorage, Alaska, United States

and more 35 locations
© Copyright 2025. All Rights Reserved by MedPath